10x Genomics Reports First Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
10x Genomics (TXG) Misses Q1 EPS by 10c; Offers FY23 Revenue Guidance
May 3, 2023 4:37 PM EDT10x Genomics (NASDAQ: TXG) reported Q1 EPS of ($0.44), $0.10 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $134.3 million versus the consensus estimate of $129.24 million.
GUIDANCE:
10x Genomics sees FY2023 revenue of $590-610 million, versus the consensus... More
